NO20072396L - Metoder for dyrking av myeloidcelle-populasjoner og anvendelser derav - Google Patents

Metoder for dyrking av myeloidcelle-populasjoner og anvendelser derav

Info

Publication number
NO20072396L
NO20072396L NO20072396A NO20072396A NO20072396L NO 20072396 L NO20072396 L NO 20072396L NO 20072396 A NO20072396 A NO 20072396A NO 20072396 A NO20072396 A NO 20072396A NO 20072396 L NO20072396 L NO 20072396L
Authority
NO
Norway
Prior art keywords
culturing
applications
methods
cell populations
myeloid cell
Prior art date
Application number
NO20072396A
Other languages
English (en)
Other versions
NO342460B1 (no
Inventor
Timothy C Fong
Adrianus Geertrudis Wilh Domen
Julie Lynne Christensen
Original Assignee
Cellerant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36228409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072396(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellerant Therapeutics Inc filed Critical Cellerant Therapeutics Inc
Publication of NO20072396L publication Critical patent/NO20072396L/no
Publication of NO342460B1 publication Critical patent/NO342460B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/44—Fungal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Foreliggende beskrivelse vedrører en fremgangsmåte for å ekspandere myeloide forløperceller ved å dyrke en opprinnelig populasjon i et medium innbefattende en blanding av cytokiner og vekstfaktorer som fremmer veksten og ekspansjonen av de myeloide forløperceller. Den ekspanderte cellepopulasjon gir en kilde for celler som terapeutisk behandling av neutropeni og/eller trombocytopeni som oppstår i pasienter som har fått myeloablativ terapi og transplantasjon av hematopoietiske stamceller.
NO20072396A 2004-10-25 2007-05-09 Fremgangsmåte for å ekspandere myeloide cellepopulasjoner, og anvendelser derav NO342460B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62231804P 2004-10-25 2004-10-25
PCT/US2005/038500 WO2006047569A2 (en) 2004-10-25 2005-10-25 Methods of expanding myeloid cell populations and uses thereof

Publications (2)

Publication Number Publication Date
NO20072396L true NO20072396L (no) 2007-07-24
NO342460B1 NO342460B1 (no) 2018-05-22

Family

ID=36228409

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072396A NO342460B1 (no) 2004-10-25 2007-05-09 Fremgangsmåte for å ekspandere myeloide cellepopulasjoner, og anvendelser derav

Country Status (14)

Country Link
US (7) US8252587B2 (no)
EP (2) EP2626415A3 (no)
JP (1) JP5519108B2 (no)
KR (2) KR20070099550A (no)
CN (2) CN101087874A (no)
AU (1) AU2005299379B2 (no)
BR (1) BRPI0516969A (no)
CA (1) CA2585343C (no)
ES (1) ES2538305T3 (no)
IL (1) IL182782A (no)
NO (1) NO342460B1 (no)
RU (1) RU2422513C2 (no)
WO (1) WO2006047569A2 (no)
ZA (1) ZA200704252B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200704252B (en) 2004-10-25 2009-09-30 Cellerant Therapeutics Inc Methods of expanding myeloid cell populations and uses thereof
US7811815B2 (en) * 2004-11-15 2010-10-12 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic uses of allogeneic myeloid progenitor cells
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
CN101421393B (zh) * 2006-02-14 2013-08-14 塞勒兰特治疗公司 提高造血干细胞植入的方法和组合物
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
US20120177610A1 (en) 2007-09-19 2012-07-12 Kieu Hoang Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins
AU2009203893B2 (en) * 2008-01-08 2014-10-02 The University Of Queensland Method of producing a population of cells
WO2010036373A2 (en) * 2008-09-26 2010-04-01 Duke University Hematopoietic stem cell growth factor
WO2010057110A1 (en) * 2008-11-14 2010-05-20 University Of Louisville Research Foundation, Inc. Methods and compositions for long term hematopoietic repopulation
JP2010193879A (ja) * 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
CN102802686A (zh) * 2009-06-18 2012-11-28 Mc2细胞有限责任公司 骨髓胞外基质提取物及其治疗用途
CN102725400A (zh) * 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法
JP2013523842A (ja) * 2010-04-09 2013-06-17 フレッド ハッチンソン キャンサー リサーチ センター 造血機能を提供するための組成物および方法
CA2795627C (en) 2010-04-09 2023-03-14 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
JP6126004B2 (ja) 2010-10-25 2017-05-10 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 血小板の生成のための組成物および方法、およびそれらの使用の方法
CN107823706B (zh) * 2010-11-10 2022-02-01 因瑞金公司 用于器官增强的注射制剂
US9476029B2 (en) * 2010-11-13 2016-10-25 Lung-Ji Chang Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
WO2013006806A1 (en) * 2011-07-06 2013-01-10 Cellerant Therapeutics, Inc. Megakaryocyte progenitor cells for production of platelets
JP6220791B2 (ja) * 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
EP2788476B1 (en) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
TW201335181A (zh) * 2012-01-31 2013-09-01 Kieu Hoang ５５種新發現的蛋白質之序列及其應用
CA2866358C (en) * 2012-03-06 2020-06-23 Cellect Biotechnology Ltd. Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof
WO2013155347A1 (en) 2012-04-11 2013-10-17 Izumi Raquel Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2014051154A1 (ja) * 2012-09-28 2014-04-03 公益財団法人先端医療振興財団 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
EP2943566A1 (en) 2013-01-08 2015-11-18 Fred Hutchinson Cancer Research Center Compositions and methods for expansion of embryonic hematopoietic stem cells
CN105377308B (zh) 2013-03-14 2019-07-26 迈兰公司 醋酸格拉替雷响应生物标志物mRNA效力测定
JP2016516758A (ja) * 2013-04-09 2016-06-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 骨髄血球減少症及び関連する合併症を予防又は治療するためのｍ−ｃｓｆの使用
EP3054961B1 (en) * 2013-10-09 2020-08-26 Cellect Biotherapeutics Ltd. Activation of hematopoietic progenitors by pretransplant exposure to death ligands
WO2015057992A1 (en) 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
US9995734B2 (en) 2013-10-24 2018-06-12 Mylan Inc. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
CN105873952A (zh) 2013-10-31 2016-08-17 弗莱德哈钦森癌症研究中心 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
JP2016104711A (ja) * 2014-11-21 2016-06-09 国立大学法人 東京大学 造血幹細胞移植を補助することに用いるための医薬組成物およびその製造方法
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
US11312940B2 (en) 2015-08-31 2022-04-26 University Of Louisville Research Foundation, Inc. Progenitor cells and methods for preparing and using the same
RU2747728C2 (ru) * 2015-12-04 2021-05-13 Фред Хатчинсон Кэнсер Рисерч Сентер Применение размноженных популяций гематопоэтических стволовых клеток/клеток-предшественников
WO2017152073A1 (en) 2016-03-04 2017-09-08 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels)
CN105713880A (zh) * 2016-04-20 2016-06-29 广东艾时代生物科技有限责任公司 一种造血干细胞体外扩增培养的无血清培养基及其应用
EP3484447A4 (en) * 2016-07-12 2020-07-22 Matinas BioPharma Nanotechnologies, Inc. ANTIFUNGAL COMPOUNDS ENCAPSULATED IN COCHLEATES FOR CENTRAL NERVOUS SYSTEM ADMINISTRATION AND TREATMENT OF CRYPTOCOCCUS INFECTIONS
EP3501278B1 (en) * 2016-08-22 2021-12-15 Bioverde Inc. Composition for cryopreservation of bovine reproductive cells and cryopreservation method therefor
GB201618106D0 (en) * 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells
CN107858330B (zh) * 2017-11-20 2021-08-27 上海中医药大学 一种小鼠骨髓造血干/祖细胞体外衰老细胞模型的建立方法
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
FR3084463B1 (fr) * 2018-07-30 2023-04-21 Francais Du Sang Ets Procede d'analyse des plaquettes d'un echantillon sanguin
WO2020056170A1 (en) 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
CN111004781A (zh) * 2018-10-08 2020-04-14 南加利福尼亚大学 长期扩增粒细胞-巨噬细胞祖细胞的方法及其应用
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
EP3945815A4 (en) * 2019-04-03 2023-04-19 Akron Biotechnology, LLC CRYOPRESERVATION AND CELL CULTURE MEDIA
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
EP3963082A4 (en) * 2019-05-01 2023-01-04 Immunebridge Inc. Methods of making oligopotent and unipotent precursors
US20220305057A1 (en) * 2019-06-06 2022-09-29 Medeor Therapeutics, Inc. Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
WO2023150089A1 (en) * 2022-02-01 2023-08-10 Bluerock Therapeutics Lp Methods for treating inherited metabolic disorders
US20250135039A1 (en) 2022-02-07 2025-05-01 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
KR20250079903A (ko) * 2023-11-27 2025-06-04 한양대학교 산학협력단 체외 배양을 통해 개의 조혈모세포나 적혈구전구세포로부터 적혈구를 생산하는 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81724T1 (de) * 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US6433142B1 (en) * 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
US6852313B1 (en) * 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5840580A (en) 1990-05-01 1998-11-24 Becton Dickinson And Company Phenotypic characterization of the hematopoietic stem cell
US6326198B1 (en) * 1990-06-14 2001-12-04 Regents Of The University Of Michigan Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
SG55145A1 (en) 1992-07-10 1998-12-21 Univ Pittsburgh Hematopoietic facilitatory cells and their uses
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
NZ271230A (en) * 1994-02-14 1998-03-25 Zymogenetics Inc Hematopoietic proteins, production and use
DE4422667A1 (de) * 1994-06-30 1996-01-04 Boehringer Ingelheim Int Verfahren zur Herstellung und Züchtung hämatopoetischer Vorläuferzellen
US6103522A (en) * 1994-07-20 2000-08-15 Fred Hutchinson Cancer Research Center Human marrow stromal cell lines which sustain hematopoiesis
US5986049A (en) * 1994-12-30 1999-11-16 Zymogenetics, Inc. Purified thrombopoietin and method of making it
US5821108A (en) * 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5925567A (en) * 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
US6013067A (en) * 1995-06-07 2000-01-11 Zymogenetics, Inc. Methods for increasing hematopoietic cells
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
DE19600589C1 (de) * 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
EP0891419A4 (en) 1996-03-12 2000-03-01 Life Technologies Inc NUTRIENT ADDITIVE FOR HEMATOPOETIC CELL CULTURES
US5843633A (en) * 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US6982082B1 (en) * 1997-08-27 2006-01-03 President And Fellows Of Harvard College Gene therapy by cell specific targeting
AU1585799A (en) * 1997-11-14 1999-06-07 General Hospital Corporation, The Treatment of hematologic disorders
CA2318819A1 (en) * 1998-02-05 1999-08-12 Novartis Ag Expanded and genetically modified populations of human hematopoietic stem cells
EP1108011A2 (en) * 1998-06-08 2001-06-20 Osiris Therapeutics, Inc. In vitro maintenance of hematopoietic stem cells
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6589759B1 (en) * 1999-03-30 2003-07-08 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
WO2000070022A2 (en) * 1999-05-14 2000-11-23 City Of Hope Ex vivo expansion of mammalian hematopoietic stem cells
US6761883B2 (en) * 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
CA2375974C (en) * 1999-06-29 2010-11-02 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
EP1248519A4 (en) * 2000-01-18 2004-03-31 Univ Leland Stanford Junior EXPANSION OF STEM AND PROCUREMENT CELLS BY BETA-CATENIN
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP1536688B1 (en) * 2002-09-13 2011-12-28 The Board Of Trustees Of The Leland Stanford Junior University Mammalian megakaryocyte progenitor cell
US6751883B2 (en) 2002-11-21 2004-06-22 Huei-Yen Liao Reel rotation mount arrangement equipped with friction reduction means for tape measure
WO2004046312A2 (en) * 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20040241856A1 (en) * 2003-02-12 2004-12-02 Irm Llc, A Delaware Limited Liability Company Methods and compositions for modulating stem cells
US20050215473A1 (en) * 2003-05-09 2005-09-29 Enrique Alvarez Prophylactic and therapeutic uses of FGF-20 in radiation protection
US20050118147A1 (en) * 2003-11-17 2005-06-02 Il-Hoan Oh Method of using mesenchymal stromal cells to increase engraftment
ZA200704252B (en) 2004-10-25 2009-09-30 Cellerant Therapeutics Inc Methods of expanding myeloid cell populations and uses thereof
US7811815B2 (en) * 2004-11-15 2010-10-12 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic uses of allogeneic myeloid progenitor cells
CN101421393B (zh) * 2006-02-14 2013-08-14 塞勒兰特治疗公司 提高造血干细胞植入的方法和组合物

Also Published As

Publication number Publication date
CN101087874A (zh) 2007-12-12
US8877495B2 (en) 2014-11-04
RU2007119401A (ru) 2008-11-27
RU2422513C2 (ru) 2011-06-27
US20220064600A1 (en) 2022-03-03
KR20070099550A (ko) 2007-10-09
EP1812555B1 (en) 2015-04-22
CN105168250B (zh) 2019-02-05
US10260044B1 (en) 2019-04-16
US20130004468A1 (en) 2013-01-03
EP1812555A4 (en) 2009-05-13
EP2626415A3 (en) 2014-04-16
KR20140027926A (ko) 2014-03-07
JP5519108B2 (ja) 2014-06-11
WO2006047569A2 (en) 2006-05-04
US20140377234A1 (en) 2014-12-25
AU2005299379A1 (en) 2006-05-04
CA2585343A1 (en) 2006-05-04
CN105168250A (zh) 2015-12-23
US8252587B2 (en) 2012-08-28
ZA200704252B (en) 2009-09-30
US8481315B2 (en) 2013-07-09
IL182782A (en) 2014-12-31
US20190241872A1 (en) 2019-08-08
IL182782A0 (en) 2007-08-19
JP2008517948A (ja) 2008-05-29
CA2585343C (en) 2016-06-21
US20060134783A1 (en) 2006-06-22
EP1812555A2 (en) 2007-08-01
US20190106680A1 (en) 2019-04-11
BRPI0516969A (pt) 2008-09-30
US20130089527A1 (en) 2013-04-11
EP2626415A2 (en) 2013-08-14
NO342460B1 (no) 2018-05-22
WO2006047569A3 (en) 2007-02-01
ES2538305T3 (es) 2015-06-18
HK1219051A1 (zh) 2017-03-24
AU2005299379B2 (en) 2011-06-09
KR101544292B1 (ko) 2015-08-12

Similar Documents

Publication Publication Date Title
NO20072396L (no) Metoder for dyrking av myeloidcelle-populasjoner og anvendelser derav
GB2432166B (en) Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
BR112022017216A2 (pt) Método para produzir células exterminadoras naturais a partir de células-tronco pluripotentes
NO20071576L (no) Middel og kulturer av embryoniske stamceller
WO2005078073A3 (en) Isolation, expansion and of clonogenic endothelial progenitor cells
WO1996006929A3 (en) Rapid expansion method ('rem') for in vitro propagation of t lymphocytes
MX2009004238A (es) Metodos y composiciones para tratamiento de defectos oseos con poblaciones de celulas de placenta.
MX2009004640A (es) Estimulacion por litio de proliferacion de celula de tallo sanguinea de cordon y produccion de factor de crecimiento.
ATE485065T1 (de) Gewebekonstruktionsvorrichtungen zur reparatur und regeneration von gewebe
WO2002061052A8 (en) An improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods
NO20053357L (no) Dyrkingsmedium, dyrkingsmetode og de oppnadde myoblaster og deres anvendelse.
WO2023288007A9 (en) Expansion of memory natural killer cells
ATE517633T1 (de) Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
US20090142318A1 (en) METHOD TO EXPAND nTREG CELLS USING p70 S6 KINASE ANTAGONIST
GB2429211A (en) Feeder independent extended culture of embryonic stem cells
CN107142241A (zh) 一种提高猪卵母细胞体外成熟质量和发育潜力的培养液及其培养方法
WO2021015615A8 (en) Low density cell culture
GB2599815A (en) Human diseased and normal kidney epithelial cell cultures and uses thereof
ATE329632T1 (de) Verfahren zur entwicklung von epithelialen stammzellen
PH12023553137A1 (en) Novel method for isolating and culturing dermal papilla cells
CL2023003083A1 (es) Métodos de expansión de células b para uso en terapia celular
ATE384121T1 (de) Verfahren zur kultivierung von menschlichen lungenmastzellen und deren anwendungen
WO2025188853A8 (en) Method of differentiation of pluripotent stem cells to natural killer cells
Sengers Modeling the development of tissue engineered cartilage.
WO2008067126A3 (en) Methods for using aldhbr cells to supplement stem cell transplantation

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees